Skip Navigation Links
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Overall Recruitment Status: Active, enrollment completed
Official Title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Region Sponsors
California - Northern
Vertex Pharmaceuticals, Inc.
Acronym KP IRB No.
Study Type Phase
Clinical Trial Phase III
Study Population Description
Male and female individuals with CF who are 12 years of age or older who are homozygous or heterozygous for the F508del mutation.
This study will evaluate the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
Detailed Description
This is a Phase 3, multicenter, open-label study for subjects who completed the last Treatment Period visit in a parent study and meet eligibility criteria. All subjects will receive the TC of VX-445/TEZ/IVA at the same dose level as that evaluated in Study 445-102 and Study 445-103.
Gender Age Limit
Male & Female
Inclusion Criteria
  • Subject (or his or her legally appointed and authorized representative) will sign and date an informed consent form (ICF), and, when appropriate, an assent form.
  • Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.
  • Did not withdraw consent from a parent study.
  • Meets at least 1 of the following criteria: (1) Completed study drug treatment in a parent study, (2) Had study drug interruption(s) in a parent study, but completed study visits up to the last scheduled visit of the Treatment Period of a parent study.
  • Willing to remain on a stable CF treatment regimen (as defined in Section 9.5) through completion of study participation.
Exclusion Criteria
  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Pregnant and nursing females. Females of childbearing potential must have a negative pregnancy test at the Day 1 Visit before receiving the first dose of study drug.
  • History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator. (e.g., subjects with a history of allergy or hypersensitivity to the study drug.)
  • Current participation in an investigational drug trial (other than a parent study). Participation in a noninterventional study (including observational studies, registry studies, and studies requiring blood collections without administration of study drug) and screening for another Vertex study is permitted.

Keywords and/or Specific Medical Conditions
  • Chloride Channel Agonists
  • Lung Diseases
  • Cystic Fibrosis
  • Membrane Transport Modulators
  • Digestive System Diseases
  • Molecular Mechanisms of Pharmacological Action
  • F508del mutation
  • Pancreatic Diseases
  • Fibrosis
  • Pathologic Processes
  • Genetic Diseases, Inborn
  • Respiratory Tract Diseases
  • Infant, Newborn, Diseases
  • Pulmonary Disease
  • Ivacaftor
KP Clinical Facility
  • Oakland Medical Center
Clinical Area
  • Pulmonary Disease

Principal Investigator:
Bryon Quick, MD
Contact Information:
- Carolyn Beebe
-Central Valley-Manteca

Do you want to receive
Email Alerts?

Sign Up Here!

Regional Research Sites: